Cabozantinib-Exposed Renal Cell Carcinoma Organoids Suggest Transcriptomic Associations with Treatment Resistance in Clear Cell and Nonclear Cell Tumors
Main Article Content
Keywords
renal cell carcinoma, cabozantinib, tyrosine kinase inhibitor, organoid, single-cell RNA sequencing
Abstract
While vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) are a mainstay of treatment for advanced renal cell carcinoma (RCC), mechanisms of resistance to VEGF-TKIs remain under ongoing investigation. To assess transcriptomic changes in clear-cell RCC (ccRCC) and non-ccRCC exposed to a VEGF-TKI, we analyzed differential single-cell gene expression in RCC tumor-organoids exposed to cabozantinib versus control solvent. In ccRCC organoid cells, LRRC75A was notably highly associated with cabozantinib exposure (log2 fold-change 2.18, detected proportion 0.52 vs. 0.23, false-detection rate adjusted p<0.001). Importantly, our findings were independently validated in a recent study of advanced ccRCC patients treated with cabozantinib, which demonstrated that higher LRRC75A expression was significantly associated with decreased tumor response and less robust reduction of VEGF expression. LRRC75A has been shown to mediate VEGF secretion in a separate study and may potentiate compensatory angiogenesis after cabozantinib exposure. Gene expression scores were then developed based on transcriptomic changes associated with cabozantinib exposure and applied to stage IV patients in several independent cohorts. Higher scores were significant predictors of worse overall survival in TCGA non-RCC patients and worse progression-free survival in JAVELIN Renal 101 ccRCC patients. Overall, this experiment represents an incremental step in a larger effort to elucidate resistance mechanisms to VEGF-TKIs.
References
2. Ishibashi K, Koguchi T, Matsuoka K, Onagi A, Tanji R, Takinami-Honda R, et al. Interleukin-6 induces drug resistance in renal cell carcinoma. Fukushima J. Med. Sci. 2018;64(3):103–10. 10.5387/fms.2018-15
3. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010 Feb 1;70:1063–71. 10.1158/0008-5472.CAN-09-3965
4. Marona P, Górka J, Kwapisz O, Jura J, Rys J, Hoffman RM, et al. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation. Cell Death Dis. 2022 Sep 22;13(9):1–17. 10.1038/s41419-022-05251-4
5. Giuliano S, Cormerais Y, Dufies M, Grépin R, Colosetti P, Belaid A, et al. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. Autophagy. 2015 Aug 27;11(10):1891–904. 10.1080/15548627.2015.1085742
6. Lindner AK, Pichler M, Thurnher M, Pichler R. Targeting c-Met to improve immune checkpoint inhibition in metastatic renal cell carcinoma. Eur. Urol. 2022 Jan 1;81(1):1–2. 10.1016/j.eururo.2021.10.025
7. Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur. Urol. 2020 Aug 1;78(2):195–206. 10.1016/j.eururo.2020.04.044
8. Park KY, Hefti HO, Liu P, Lugo-Cintrón KM, Kerr SC, Beebe DJ. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma. Integr. Biol. 2021 Dec 21;13(11):259–68. 10.1093/intbio/zyab018
9. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016 Jan 4;44(D1):D457–62. 10.1093/nar/gkv1070
10. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016 Jul 8;44(W1):W90–97. 10.1093/nar/gkw377
11. Bilen MA, Vo BT, Liu Y, Greenwald R, Davarpanah AH, McGuire D, et al. Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. Nat. Cancer. 2025 Mar 6(3):432–44. 10.1038/s43018-025-00922-5
12. TCGA-KIRC [Internet]. The Cancer Imaging Archive (TCIA). [cited 2025 Feb 11]. Available from: https://www.cancerimagingarchive.net/collection/tcga-kirc/
13. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019 Mar 21;380(12):1103–15. 10.1056/NEJMoa1816047
14. TCGA-KIRP [Internet]. The Cancer Imaging Archive (TCIA). [cited 2025 Feb 11]. Available from: https://www.cancerimagingarchive.net/collection/tcga-kirp/
15. Miura T, Kouno T, Takano M, Kuroda T, Yamamoto Y, Kusakawa S, et al. Single-cell RNA-seq reveals LRRC75A-expressing cell population involved in VEGF secretion of multipotent mesenchymal stromal/stem cells under ischemia. Stem Cells Transl. Med. 2023 Jun 15;12(6):379–90. 10.1093/stcltm/szad029
16. Gomes CP, Nóbrega-Pereira S, Domingues-Silva B, Rebelo K, Alves-Vale C, Marinho SP, et al. An antisense transcript mediates MALAT1 response in human breast cancer. BMC Cancer. 2019 Aug 5;19:771. 10.1186/s12885-019-5962-0
17. Hlady RA, Novakova S, Opavska J, Klinkebiel D, Peters SL, Bies J, et al. Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J. Clin. Invest. 2012 Jan 3;122(1):163–77. 10.1172/JCI57292
18. Wang D, Deng L, Xu X, Ji Y, Jiao Z. Elevated SYNC expression is associated with gastric tumorigenesis and infiltration of M2-polarized macrophages in the gastric tumor immune microenvironment. Genet. Test Mol. Biomark. 2021 Mar 25(3):236–46. 10.1089/gtmb.2020.0131
19. Messai Y, Noman MZ, Hasmim M, Janji B, Tittarelli A, Boutet M, et al. ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. Cancer Res. 2014 Nov 30;74(23):6820–32. 10.1158/0008-5472.CAN-14-0303
20. Ryland KE, Svoboda LK, Vesely ED, McIntyre JC, Zhang L, Martens JR, et al. Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stress. Oncogene. 2015 Aug 27;34(35):4591–600. 10.1038/onc.2014.384
21. Yang X, Han B, Xie Q, Li Y, Li Q, Hu X, et al. Low expression of mitochondrial ribosomal protein S5 is associated with poor prognosis in patients with clear cell renal cell carcinoma. Appl. Immunohistochem. Mol. Morphol. AIMM. 2025 Jan 1;33(1):22–8. 10.1097/PAI.0000000000001236
22. An HJ, Koh HM, Lee JS, Song DH. Prognostic role of macrophage migration inhibitory factor in patients with clear cell renal cell carcinoma. Medicine (Baltimore). 2020 Dec 11;99(50):e23277. 10.1097/MD.0000000000023277
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.